

Devin Oglesbee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5816324/publications.pdf>

Version: 2024-02-01

74
papers

4,086
citations

117625

34
h-index

118850

62
g-index

79
all docs

79
docs citations

79
times ranked

6145
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical characterization of primary hyperoxaluria type 3 in comparison with types 1 and 2. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 869-875.	0.7	23
2	Bile Acid Profiles in Primary Sclerosing Cholangitis and Their Ability to Predict Hepatic Decompensation. <i>Hepatology</i> , 2021, 74, 281-295.	7.3	40
3	Laboratory analysis of acylcarnitines, 2020 update: a technical standard of the American College of Medical Genetics and Genomics (ACMG). <i>Genetics in Medicine</i> , 2021, 23, 249-258.	2.4	19
4	Immune dysfunction in MGAT2â€CDG : A clinical report and review of the literature. <i>American Journal of Medical Genetics, Part A</i> , 2021, 185, 213-218.	1.2	5
5	Clinical sites of the Undiagnosed Diseases Network: unique contributions to genomic medicine and science. <i>Genetics in Medicine</i> , 2021, 23, 259-271.	2.4	18
6	Circulating markers of NADH-reductive stress correlate with mitochondrial disease severity. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	95
7	The low excretor phenotype of glutaric acidemia type I is a source of false negative newborn screening results and challenging diagnoses. <i>JIMD Reports</i> , 2021, 60, 67-74.	1.5	4
8	Cerebellar and multi-system metabolic reprogramming associated with trauma exposure and post-traumatic stress disorder (PTSD)-like behavior in mice. <i>Neurobiology of Stress</i> , 2021, 14, 100300.	4.0	4
9	A new <sc>Dâ€galactose</sc> treatment monitoring index for <sc>PGM1â€CDG</sc>. <i>Journal of Inherited Metabolic Disease</i> , 2021, 44, 1263-1271.	3.6	10
10	High-resolution mass spectrometric analysis of cardiolipin profiles in Barth syndrome. <i>Mitochondrion</i> , 2021, 60, 27-32.	3.4	2
11	Sorbitol Is a Severity Biomarker for <sc>PMM2â€CDG</sc> with Therapeutic Implications. <i>Annals of Neurology</i> , 2021, 90, 887-900.	5.3	22
12	Laboratory screening and diagnosis of open neural tube defects, 2019 revision: a technical standard of the American College of Medical Genetics and Genomics (ACMG). <i>Genetics in Medicine</i> , 2020, 22, 462-474.	2.4	23
13	Multiplex testing for the screening of lysosomal storage disease in urine: Sulfatides and glycosaminoglycan profiles in 40 cases of sulfatiduria. <i>Molecular Genetics and Metabolism</i> , 2020, 129, 106-110.	1.1	10
14	An activating germline IDH1 variant associated with a tumor entity characterized by unilateral and bilateral chondrosarcoma of the mastoid. <i>Human Genetics and Genomics Advances</i> , 2020, 1, 100006.	1.7	3
15	Laboratory monitoring of patients with hereditary tyrosinemia type I. <i>Molecular Genetics and Metabolism</i> , 2020, 130, 247-254.	1.1	4
16	De novo EIF2AK1 and EIF2AK2 Variants Are Associated with Developmental Delay, Leukoencephalopathy, and Neurologic Decompensation. <i>American Journal of Human Genetics</i> , 2020, 106, 570-583.	6.2	37
17	Risk categorization for oversight of laboratory-developed tests for inherited conditions: an updated position statement of the American College of Medical Genetics and Genomics (ACMG). <i>Genetics in Medicine</i> , 2020, 22, 983-985.	2.4	0
18	A Comparative Effectiveness Study of Newborn Screening Methods for Four Lysosomal Storage Disorders. <i>International Journal of Neonatal Screening</i> , 2020, 6, 44.	3.2	23

#	ARTICLE	IF	CITATIONS
19	Incorporation of Second-Tier Biomarker Testing Improves the Specificity of Newborn Screening for Mucopolysaccharidosis Type I. <i>International Journal of Neonatal Screening</i> , 2020, 6, 10.	3.2	32
20	The critical role of psychosine in screening, diagnosis, and monitoring of Krabbe disease. <i>Genetics in Medicine</i> , 2020, 22, 1108-1118.	2.4	39
21	The Combined Impact of CLIR Post-Analytical Tools and Second Tier Testing on the Performance of Newborn Screening for Disorders of Propionate, Methionine, and Cobalamin Metabolism. <i>International Journal of Neonatal Screening</i> , 2020, 6, 33.	3.2	19
22	m.3243A > G-Induced Mitochondrial Dysfunction Impairs Human Neuronal Development and Reduces Neuronal Network Activity and Synchronicity. <i>Cell Reports</i> , 2020, 31, 107538.	6.4	56
23	Characterising a healthy adult with a rare HAO1 knockout to support a therapeutic strategy for primary hyperoxaluria. <i>ELife</i> , 2020, 9, .	6.0	45
24	De Novo Variants in WDR37 Are Associated with Epilepsy, Colobomas, Dysmorphism, Developmental Delay, Intellectual Disability, and Cerebellar Hypoplasia. <i>American Journal of Human Genetics</i> , 2019, 105, 413-424.	6.2	43
25	Magnetic Resonance Imaging characteristics in case of TOR1AIP1 muscular dystrophy. <i>Clinical Imaging</i> , 2019, 58, 108-113.	1.5	6
26	A tailored approach to fusion transcript identification increases diagnosis of rare inherited disease. <i>PLoS ONE</i> , 2019, 14, e0223337.	2.5	27
27	De Novo Pathogenic Variants in N-cadherin Cause a Syndromic Neurodevelopmental Disorder with Corpus Callosum, Axon, Cardiac, Ocular, and Genital Defects. <i>American Journal of Human Genetics</i> , 2019, 105, 854-868.	6.2	29
28	Lysosomal Storage and Albinism Due to Effects of a De Novo CLCN7 Variant on Lysosomal Acidification. <i>American Journal of Human Genetics</i> , 2019, 104, 1127-1138.	6.2	59
29	A missense variant in FTCD is associated with arsenic metabolism and toxicity phenotypes in Bangladesh. <i>PLoS Genetics</i> , 2019, 15, e1007984.	3.5	19
30	CAP/ACMG proficiency testing for biochemical genetics laboratories: a summary of performance. <i>Genetics in Medicine</i> , 2018, 20, 83-90.	2.4	7
31	Moonlighting newborn screening markers: the incidental discovery of a second-tier test for Pompe disease. <i>Genetics in Medicine</i> , 2018, 20, 840-846.	2.4	44
32	Precision newborn screening for lysosomal disorders. <i>Genetics in Medicine</i> , 2018, 20, 847-854.	2.4	99
33	Multiplex Droplet Digital PCR Method Applicable to Newborn Screening, Carrier Status, and Assessment of Spinal Muscular Atrophy. <i>Clinical Chemistry</i> , 2018, 64, 1753-1761.	3.2	45
34	Composition of single-step media used for human embryo culture. <i>Fertility and Sterility</i> , 2017, 107, 1055-1060.e1.	1.0	61
35	A Droplet Digital PCR Method for Severe Combined Immunodeficiency Newborn Screening. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 755-765.	2.8	14
36	Mitochondrial DNA sequence data reveals association of haplogroup U with psychosis in bipolar disorder. <i>Journal of Psychiatric Research</i> , 2017, 84, 221-226.	3.1	15

#	ARTICLE	IF	CITATIONS
37	Mitochondrial 3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency: Unique Presenting Laboratory Values and a Review of Biochemical and Clinical Features. <i>JIMD Reports</i> , 2017, 40, 63-69.	1.5	27
38	Allelic spectrum of formiminotransferaseâ€cyclodeaminase gene variants in individuals with formiminoglutamic aciduria. <i>Molecular Genetics & Genomic Medicine</i> , 2017, 5, 795-799.	1.2	14
39	Natural underlying mt<sc>DNA</sc> heteroplasmy as a potential source of intraâ€person hi<sc>PSC</sc> variability. <i>EMBO Journal</i> , 2016, 35, 1979-1990.	7.8	71
40	Simultaneous Testing for 6 Lysosomal Storage Disorders and X-Adrenoleukodystrophy in Dried Blood Spots by Tandem Mass Spectrometry. <i>Clinical Chemistry</i> , 2016, 62, 1248-1254.	3.2	37
41	Silent Tyrosinemia Type I Without Elevated Tyrosine or Succinylacetone Associated with Liver Cirrhosis and Hepatocellular Carcinoma. <i>Human Mutation</i> , 2016, 37, 1097-1105.	2.5	21
42	Outcome of Whole Exome Sequencing for Diagnostic Odyssey Cases of an Individualized Medicine Clinic. <i>Mayo Clinic Proceedings</i> , 2016, 91, 297-307.	3.0	83
43	Outcomes of four patients with homocysteine remethylation disorders detected by newborn screening. <i>Genetics in Medicine</i> , 2016, 18, 162-167.	2.4	21
44	Human Genetic Disorders. , 2016, , 595-663.		1
45	Newborn screening for lysosomal storage disorders. <i>Seminars in Perinatology</i> , 2015, 39, 206-216.	2.5	91
46	Streamlined determination of lysophosphatidylcholines in dried blood spots for newborn screening of X-linked adrenoleukodystrophy. <i>Molecular Genetics and Metabolism</i> , 2015, 114, 46-50.	1.1	54
47	Confirming Variants in Next-Generation Sequencing Panel Testing by Sanger Sequencing. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 456-461.	2.8	109
48	Measurement of psychosine in dried blood spots â€” a possible improvement to newborn screening programs for Krabbe disease. <i>Journal of Inherited Metabolic Disease</i> , 2015, 38, 923-929.	3.6	59
49	Usefulness of frataxin immunoassays for the diagnosis of Friedreich ataxia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 994-1002.	1.9	14
50	Newborn screening for lysosomal storage disorders and other neuronopathic conditions. <i>Developmental Disabilities Research Reviews</i> , 2013, 17, 247-253.	2.9	38
51	Aripiprazole and trazodone cause elevations of 7-dehydrocholesterol in the absence of Smithâ€Lemliâ€Opitz Syndrome. <i>Molecular Genetics and Metabolism</i> , 2013, 110, 176-178.	1.1	34
52	Disease-Causing Mitochondrial Heteroplasmy Segregated Within Induced Pluripotent Stem Cell Clones Derived from a Patient with MELAS. <i>Stem Cells</i> , 2013, 31, 1298-1308.	3.2	112
53	High-Throughput Immunoassay for the Biochemical Diagnosis of Friedreich Ataxia in Dried Blood Spots and Whole Blood. <i>Clinical Chemistry</i> , 2013, 59, 1461-1469.	3.2	10
54	Enhanced interpretation of newborn screening results without analyte cutoff values. <i>Genetics in Medicine</i> , 2012, 14, 648-655.	2.4	117

#	ARTICLE	IF	CITATIONS
55	Design and Analytical Validation of Clinical DNA Sequencing Assays. Archives of Pathology and Laboratory Medicine, 2012, 136, 41-46.	2.5	35
56	Clinical validation of cutoff target ranges in newborn screening of metabolic disorders by tandem mass spectrometry: A worldwide collaborative project. Genetics in Medicine, 2011, 13, 230-254.	2.4	308
57	Co-morbidity of Sanfilippo Syndrome type C and d-2-hydroxyglutaric aciduria. Journal of Neurology, 2011, 258, 1564-1565.	3.6	7
58	Unexpected Fabry Disease in a Renal Allograft Kidney: An Underrecognized Cause of Poor Allograft Function. Ultrastructural Pathology, 2011, 35, 92-96.	0.9	6
59	Two-Tier Approach to the Newborn Screening of Methylenetetrahydrofolate Reductase Deficiency and Other Remethylation Disorders with Tandem Mass Spectrometry. Journal of Pediatrics, 2010, 157, 271-275.	1.8	43
60	Determination of Total Homocysteine, Methylmalonic Acid, and 2-Methylcitric Acid in Dried Blood Spots by Tandem Mass Spectrometry. Clinical Chemistry, 2010, 56, 1686-1695.	3.2	121
61	Homogentisic acid interference in routine urine creatinine determination. Molecular Genetics and Metabolism, 2010, 100, 103-104.	1.1	13
62	Allelic diversity in MCAD deficiency: The biochemical classification of 54 variants identified during 5years of ACADM sequencing. Molecular Genetics and Metabolism, 2010, 100, 241-250.	1.1	58
63	An adult onset case of alpha-methylacyl-CoA racemase deficiency. Journal of Inherited Metabolic Disease, 2010, 33, 349-353.	3.6	32
64	Combined Newborn Screening for Succinylacetone, Amino Acids, and Acylcarnitines in Dried Blood Spots. Clinical Chemistry, 2008, 54, 657-664.	3.2	138
65	Second-Tier Test for Quantification of Alloisoleucine and Branched-Chain Amino Acids in Dried Blood Spots to Improve Newborn Screening for Maple Syrup Urine Disease (MSUD). Clinical Chemistry, 2008, 54, 542-549.	3.2	114
66	Development of a newborn screening follow-up algorithm for the diagnosis of isobutyryl-CoA dehydrogenase deficiency. Genetics in Medicine, 2007, 9, 108-116.	2.4	50
67	Reduction of the false-positive rate in newborn screening by implementation of MS/MS-based second-tier tests: The Mayo Clinic experience (2004-2007). Journal of Inherited Metabolic Disease, 2007, 30, 585-592.	3.6	189
68	Normal Muscle Respiratory Chain Enzymes Can Complicate Mitochondrial Disease Diagnosis. Pediatric Neurology, 2006, 35, 289-292.	2.1	16
69	Automated Spectrophotometric Analysis of Mitochondrial Respiratory Chain Complex Enzyme Activities in Cultured Skin Fibroblasts. Clinical Chemistry, 2005, 51, 2110-2116.	3.2	51
70	An overview of peroxisomal biogenesis disorders. Molecular Genetics and Metabolism, 2005, 84, 299-301.	1.1	11
71	Investigating Mitochondrial Redox Potential with Redox-sensitive Green Fluorescent Protein Indicators. Journal of Biological Chemistry, 2004, 279, 13044-13053.	3.4	846
72	The Subunit Composition of the Human NADH Dehydrogenase Obtained by Rapid One-step Immunopurification. Journal of Biological Chemistry, 2003, 278, 13619-13622.	3.4	93

#	ARTICLE	IF	CITATIONS
73	A replicating module as the unit of mitochondrial structure and functioning. <i>Biochimica Et Biophysica Acta - Bioenergetics</i> , 2002, 1555, 192-195.	1.0	24
74	Laboratory Diagnosis of Inborn Errors of Metabolism. , 0, , 531-544.		1